New EU Restrictions On Biogen’s MS Drug Zinbryta Are ‘Damaging’, Analyst Warns

 
• By Neena Brizmohun

Biogen is to continue to work closely with the EMA on clear guidance on how to use its MS drug Zinbryta, after the regulators recommended further restrictions on the product’s use because of the risk of liver damage. But an analyst says the restrictions are detrimental for the drug.

Multiple Sclerosis
The EMA is placing further restrictions on the use of Biogen's MS drug

More from Drug Safety

More from Pink Sheet